Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 459

1.

Combined Immunofluorescence, RNA FISH, and DNA FISH in Preimplantation Mouse Embryos.

Okamoto I.

Methods Mol Biol. 2018;1861:149-159. doi: 10.1007/978-1-4939-8766-5_12.

PMID:
30218366
2.

Spontaneous and Direct Transformation of N,O-Diaryl Carbamates into N,N'-Diarylureas.

Yamasaki R, Honjo Y, Ito A, Fukuda K, Okamoto I.

Chem Pharm Bull (Tokyo). 2018;66(9):880-884. doi: 10.1248/cpb.c18-00394.

3.

Concomitant Extramedullary Plasmacytoma in the Oropharynx and Hypopharyngeal Squamous Cell Carcinoma.

Sato H, Yoshimasu S, Okamoto I, Shimizu A, Katsube Y, Tanaka H, Tsukahara K.

Case Rep Otolaryngol. 2018 Jul 31;2018:1463218. doi: 10.1155/2018/1463218. eCollection 2018.

4.

CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Reungwetwattana T, Nakagawa K, Cho BC, Cobo M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam SS, Vansteenkiste J.

J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118. [Epub ahead of print]

PMID:
30153097
5.

Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis.

Ide M, Tanaka K, Sunami S, Asoh T, Maeyama T, Tsuruta N, Nakanishi Y, Okamoto I.

Thorac Cancer. 2018 Aug 28. doi: 10.1111/1759-7714.12853. [Epub ahead of print]

PMID:
30152594
6.

Reuse of intermittent catheters: a qualitative study of IC users' perspectives.

Avery M, Prieto J, Okamoto I, Cullen S, Clancy B, Moore KN, Macaulay M, Fader M.

BMJ Open. 2018 Aug 17;8(8):e021554. doi: 10.1136/bmjopen-2018-021554.

7.

Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade.

Tanaka K, Yanagihara T, Ikematsu Y, Inoue H, Ota K, Kashiwagi E, Suzuki K, Hamada N, Takeuchi A, Tatsugami K, Eto M, Ijichi K, Oda Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I.

Oncotarget. 2018 Jul 17;9(55):30587-30593. doi: 10.18632/oncotarget.25743. eCollection 2018 Jul 17.

8.

Contributions by MC1R Variants to Melanoma Risk in Males and Females.

Wendt J, Mueller C, Rauscher S, Fae I, Fischer G, Okamoto I.

JAMA Dermatol. 2018 Jul 1;154(7):789-795. doi: 10.1001/jamadermatol.2018.1252.

PMID:
29898205
9.

A Case of Septicemia due to Nonocclusive Mesenteric Ischemia Occurring in Induction Chemotherapy.

Tanaka H, Tsukahara K, Okamoto I, Kojima R, Hirasawa K, Sato H.

Case Rep Otolaryngol. 2018 Apr 19;2018:7426819. doi: 10.1155/2018/7426819. eCollection 2018.

10.

Anticancer drug treatment for advanced lung cancer with interstitial lung disease.

Otsubo K, Okamoto I, Hamada N, Nakanishi Y.

Respir Investig. 2018 Jul;56(4):307-311. doi: 10.1016/j.resinv.2018.03.002. Epub 2018 Apr 13. Review.

PMID:
29764748
11.

Expression of brain-derived neurotrophic factor and its receptor TrkB is associated with poor prognosis and a malignant phenotype in small cell lung cancer.

Kimura S, Harada T, Ijichi K, Tanaka K, Liu R, Shibahara D, Kawano Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I.

Lung Cancer. 2018 Jun;120:98-107. doi: 10.1016/j.lungcan.2018.04.005. Epub 2018 Apr 5.

PMID:
29748024
12.

CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study.

Vansteenkiste J, Reungwetwattana T, Nakagawa K, Cho BC, Dols MAC, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkov Y, Ramalingam S.

Ann Oncol. 2017 Nov 1;28(suppl_10). doi: 10.1093/annonc/mdx782. No abstract available.

PMID:
29718073
13.

Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.

Akamatsu H, Katakami N, Okamoto I, Kato T, Kim YH, Imamura F, Shinkai M, Hodge RA, Uchida H, Hida T.

Cancer Sci. 2018 Jun;109(6):1930-1938. doi: 10.1111/cas.13623. Epub 2018 May 31.

14.

Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.

Shibahara D, Tanaka K, Iwama E, Kubo N, Ota K, Azuma K, Harada T, Fujita J, Nakanishi Y, Okamoto I.

J Thorac Oncol. 2018 Jul;13(7):926-937. doi: 10.1016/j.jtho.2018.03.012. Epub 2018 Mar 27.

PMID:
29596910
15.

PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements.

Yoneshima Y, Ijichi K, Anai S, Ota K, Otsubo K, Iwama E, Tanaka K, Oda Y, Nakanishi Y, Okamoto I.

Lung Cancer. 2018 Apr;118:36-40. doi: 10.1016/j.lungcan.2018.01.024. Epub 2018 Feb 2.

PMID:
29572000
16.

Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.

Akamine T, Takada K, Toyokawa G, Kinoshita F, Matsubara T, Kozuma Y, Haratake N, Takamori S, Hirai F, Tagawa T, Okamoto T, Yoneshima Y, Okamoto I, Shimokawa M, Oda Y, Nakanishi Y, Maehara Y.

Surg Oncol. 2018 Mar;27(1):88-94. doi: 10.1016/j.suronc.2018.01.002. Epub 2018 Jan 9.

PMID:
29549910
17.

Germline Variants in the POT1-Gene in High-Risk Melanoma Patients in Austria.

Müller C, Krunic M, Wendt J, von Haeseler A, Okamoto I.

G3 (Bethesda). 2018 May 4;8(5):1475-1480. doi: 10.1534/g3.117.300394.

18.

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort.

Okamoto I, Morita S, Tashiro N, Imamura F, Inoue A, Seto T, Yamamoto N, Ohe Y, Nakagawa K, Fukuoka M.

Lung Cancer. 2018 Mar;117:14-19. doi: 10.1016/j.lungcan.2018.01.005. Epub 2018 Jan 9.

19.

Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.

Kiura K, Imamura F, Kagamu H, Matsumoto S, Hida T, Nakagawa K, Satouchi M, Okamoto I, Takenoyama M, Fujisaka Y, Kurata T, Ito M, Tokushige K, Hatano B, Nishio M.

Jpn J Clin Oncol. 2018 Apr 1;48(4):367-375. doi: 10.1093/jjco/hyy016.

20.

Chemoradiotherapy With Generic Cisplatin Formulations for Head and Neck Cancers.

Shimada R, Tsukahara K, Takase S, Okamoto I, Sato H, Katsube Y, Maruyama R, Shimizu A.

Jpn Clin Med. 2018 Jan 29;9:1179670717749231. doi: 10.1177/1179670717749231. eCollection 2018.

21.

Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer.

Iwama E, Nakanishi Y, Okamoto I.

Expert Rev Anticancer Ther. 2018 Mar;18(3):267-276. doi: 10.1080/14737140.2018.1432356. Epub 2018 Jan 27.

PMID:
29363369
22.

Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.

Kiura K, Yoh K, Katakami N, Nogami N, Kasahara K, Takahashi T, Okamoto I, Cantarini M, Hodge R, Uchida H.

Cancer Sci. 2018 Apr;109(4):1177-1184. doi: 10.1111/cas.13511. Epub 2018 Feb 27.

23.

Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.

Tanaka K, Isse K, Fujihira T, Takenoyama M, Saunders L, Bheddah S, Nakanishi Y, Okamoto I.

Lung Cancer. 2018 Jan;115:116-120. doi: 10.1016/j.lungcan.2017.11.018. Epub 2017 Nov 22.

PMID:
29290251
24.

Clinical Significance of PD-L1 Expression in Brain Metastases from Non-small Cell Lung Cancer.

Takamori S, Toyokawa G, Okamoto I, Takada K, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Mukae N, Hirai F, Tagawa T, Oda Y, Iwaki T, Iihara K, Nakanishi Y, Maehara Y.

Anticancer Res. 2018 Jan;38(1):553-557.

PMID:
29277823
25.

Metastatic Lung Adenocarcinoma Mimicking Meningioma.

Yanagihara T, Seki N, Hiwatashi A, Arimura K, O Suzuki S, Okamoto I.

Intern Med. 2018 Apr 1;57(7):1057-1058. doi: 10.2169/internalmedicine.9472-17. Epub 2017 Dec 21. No abstract available.

26.

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators.

N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.

27.

CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment.

Kawano Y, Iwama E, Tsuchihashi K, Shibahara D, Harada T, Tanaka K, Nagano O, Saya H, Nakanishi Y, Okamoto I.

Lung Cancer. 2017 Nov;113:72-78. doi: 10.1016/j.lungcan.2017.09.008. Epub 2017 Sep 14.

PMID:
29110853
28.

Contribution of epigenetic landscapes and transcription factors to X-chromosome reactivation in the inner cell mass.

Borensztein M, Okamoto I, Syx L, Guilbaud G, Picard C, Ancelin K, Galupa R, Diabangouaya P, Servant N, Barillot E, Surani A, Saitou M, Chen CJ, Anastassiadis K, Heard E.

Nat Commun. 2017 Nov 3;8(1):1297. doi: 10.1038/s41467-017-01415-5.

29.

Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small-cell lung cancer.

Otsubo K, Seki N, Nakanishi Y, Okamoto I.

Ann Oncol. 2018 Mar 1;29(3):780-781. doi: 10.1093/annonc/mdx700. No abstract available.

PMID:
29088405
30.

Visualization and quantitation of epidermal growth factor receptor homodimerization and activation with a proximity ligation assay.

Ota K, Harada T, Otsubo K, Fujii A, Tsuchiya Y, Tanaka K, Okamoto I, Nakanishi Y.

Oncotarget. 2017 Jul 25;8(42):72127-72132. doi: 10.18632/oncotarget.19552. eCollection 2017 Sep 22.

31.

Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment Groups.

Yabuuchi H, Kawanami S, Iwama E, Okamoto I, Kamitani T, Sagiyama K, Yamasaki Y, Honda H.

Radiology. 2018 Feb;286(2):685-695. doi: 10.1148/radiol.2017162204. Epub 2017 Oct 23.

PMID:
29059037
32.

Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results.

Kato T, Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I, Tao L, Yu W, Khaznadar T, Tajima K, Shibata M, Seki A, Yamamoto N.

Drug Saf. 2018 Feb;41(2):229-237. doi: 10.1007/s40264-017-0596-0.

33.

Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionization mass spectrometry imaging: a pilot study.

Ryu S, Hayashi M, Aikawa H, Okamoto I, Fujiwara Y, Hamada A.

Br J Pharmacol. 2018 Jan;175(1):29-37. doi: 10.1111/bph.14067. Epub 2017 Nov 6.

PMID:
29027209
34.

Parapharyngeal space tumor surgery using a modified cervical-parotid approach.

Okamoto I, Tsukahara K, Sato H.

Acta Otolaryngol. 2018 Feb;138(2):165-169. doi: 10.1080/00016489.2017.1384058. Epub 2017 Oct 5.

PMID:
28978266
35.

Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations.

Tanaka K, Nosaki K, Otsubo K, Azuma K, Sakata S, Ouchi H, Morinaga R, Wataya H, Fujii A, Nakagaki N, Tsuruta N, Takeshita M, Iwama E, Harada T, Nakanishi Y, Okamoto I.

Oncotarget. 2017 Jul 12;8(40):68123-68130. doi: 10.18632/oncotarget.19243. eCollection 2017 Sep 15.

36.

Two cases of late-onset secondary adrenal insufficiency after discontinuation of nivolumab.

Otsubo K, Nakatomi K, Furukawa R, Ashida K, Yoneshima Y, Nakanishi Y, Okamoto I.

Ann Oncol. 2017 Dec 1;28(12):3106-3107. doi: 10.1093/annonc/mdx497. No abstract available.

PMID:
28945828
37.

Intermittent catheter users' symptom identification, description and management of urinary tract infection: a qualitative study.

Okamoto I, Prieto J, Avery M, Moore K, Fader M, Sartain S, Clancy B.

BMJ Open. 2017 Sep 3;7(9):e016453. doi: 10.1136/bmjopen-2017-016453.

38.

Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1.

Ikematsu Y, Yoneshima Y, Ijichi K, Tanaka K, Harada T, Oda Y, Nakanishi Y, Okamoto I.

Lung Cancer. 2017 Oct;112:230-231. doi: 10.1016/j.lungcan.2017.07.020. Epub 2017 Jul 21. No abstract available.

PMID:
28754417
39.

Mild pulmonary emphysema a risk factor for interstitial lung disease when using cetuximab for squamous cell carcinoma of the head and neck.

Okamoto I, Tsukahara K, Sato H, Motohashi R, Yunaiyama D, Shimizu A.

Acta Otolaryngol. 2017 Dec;137(12):1288-1291. doi: 10.1080/00016489.2017.1355566. Epub 2017 Jul 25.

PMID:
28741444
40.

Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer.

Takamori S, Toyokawa G, Okamoto I, Takada K, Kozuma Y, Matsubara T, Haratake N, Akamine T, Katsura M, Mukae N, Shoji F, Okamoto T, Oda Y, Iwaki T, Iihara K, Nakanishi Y, Maehara Y.

Anticancer Res. 2017 Aug;37(8):4223-4228.

PMID:
28739710
41.

Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis.

Otsubo K, Kishimoto J, Kenmotsu H, Minegishi Y, Ichihara E, Shiraki A, Kato T, Atagi S, Horinouchi H, Ando M, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakanishi Y, Okamoto I.

Clin Lung Cancer. 2018 Jan;19(1):e5-e9. doi: 10.1016/j.cllc.2017.06.003. Epub 2017 Jun 20.

PMID:
28687482
42.

Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer.

Otsubo K, Nosaki K, Imamura CK, Ogata H, Fujita A, Sakata S, Hirai F, Toyokawa G, Iwama E, Harada T, Seto T, Takenoyama M, Ozeki T, Mushiroda T, Inada M, Kishimoto J, Tsuchihashi K, Suina K, Nagano O, Saya H, Nakanishi Y, Okamoto I.

Cancer Sci. 2017 Sep;108(9):1843-1849. doi: 10.1111/cas.13309. Epub 2017 Jul 26.

43.

Single-cell transcriptome of early embryos and cultured embryonic stem cells of cynomolgus monkeys.

Nakamura T, Yabuta Y, Okamoto I, Sasaki K, Iwatani C, Tsuchiya H, Saitou M.

Sci Data. 2017 Jun 20;4:170067. doi: 10.1038/sdata.2017.67. eCollection 2017.

44.

Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non-small cell lung cancer.

Hidaka N, Iwama E, Kubo N, Harada T, Miyawaki K, Tanaka K, Okamoto I, Baba E, Akashi K, Sasaki H, Nakanishi Y.

Lung Cancer. 2017 Jun;108:75-82. doi: 10.1016/j.lungcan.2017.02.019. Epub 2017 Mar 1.

PMID:
28625653
45.

A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.

Hayashi H, Chiba Y, Sakai K, Fujita T, Yoshioka H, Sakai D, Kitagawa C, Naito T, Takeda K, Okamoto I, Mitsudomi T, Kawakami Y, Nishio K, Nakamura S, Yamamoto N, Nakagawa K.

Clin Lung Cancer. 2017 Nov;18(6):719-723. doi: 10.1016/j.cllc.2017.05.012. Epub 2017 May 25.

PMID:
28623122
46.

In vitro expansion of mouse primordial germ cell-like cells recapitulates an epigenetic blank slate.

Ohta H, Kurimoto K, Okamoto I, Nakamura T, Yabuta Y, Miyauchi H, Yamamoto T, Okuno Y, Hagiwara M, Shirane K, Sasaki H, Saitou M.

EMBO J. 2017 Jul 3;36(13):1888-1907. doi: 10.15252/embj.201695862. Epub 2017 May 30.

47.

Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment.

Yanagihara T, Tanaka K, Ota K, Kashiwagi E, Takeuchi A, Tatsugami K, Eto M, Nakanishi Y, Okamoto I.

Ann Oncol. 2017 Aug 1;28(8):2038-2039. doi: 10.1093/annonc/mdx214. No abstract available.

PMID:
28459940
48.

RNA FISH to Study Zygotic Genome Activation in Early Mouse Embryos.

Ranisavljevic N, Okamoto I, Heard E, Ancelin K.

Methods Mol Biol. 2017;1605:133-145. doi: 10.1007/978-1-4939-6988-3_9.

PMID:
28456962
49.

Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.

Ogata H, Yamamoto Y, Harada T, Nakanishi Y, Okamoto I, Iwama E, Kato K, Oda Y.

J Thorac Oncol. 2017 May;12(5):e46-e47. doi: 10.1016/j.jtho.2016.12.023. No abstract available.

50.

Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Yoneshima Y, Morita S, Ando M, Miura S, Yoshioka H, Abe T, Kato T, Kondo M, Hosomi Y, Hotta K, Yamamoto N, Kishimoto J, Nakanishi Y, Okamoto I.

Clin Lung Cancer. 2017 Jan;18(1):100-103. doi: 10.1016/j.cllc.2016.08.003. Epub 2016 Oct 3.

PMID:
28341108

Supplemental Content

Loading ...
Support Center